Gatifloxacin hydrochloride is a fourth-generation broad-spectrum fluoroquinolone antibiotic used clinically for the treatment of moderate to severe infections caused by susceptible strains, including: (1) acute exacerbations of chronic bronchitis due to Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Staphylococcus aureus; (2) acute sinusitis caused by S. pneumoniae or H. influenzae; (3) community-acquired pneumonia due to S. pneumoniae, H. influenzae, H. parainfluenzae, M. catarrhalis, S. aureus, Chlamydophila pneumoniae, Mycoplasma pneumoniae, or Legionella pneumophila; (4) uncomplicated or complicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis; (5) pyelonephritis due to E. coli; (6) uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae; and (7) acute uncomplicated rectal infections in females due to N. gonorrhoeae. It is also formulated as a 0.3% ophthalmic solution for the treatment of ocular infections, being the first fourth-generation fluoroquinolone approved for this indication. Gatifloxacin exhibits broad in vitro activity against Gram-positive and Gram-negative bacteria as well as atypical pathogens, acting by inhibiting bacterial DNA gyrase and topoisomerase IV, thereby interfering with DNA replication, transcription, and repair.